First Human CRISPR Trials By Editas Gets FDA Approval
--Sharing is Caring--

First Human CRISPR Trials By Editas Gets FDA Approval

Editas is back in the race after a prolonged absence. In a revolutionary decision, FDA has approved Editas IND application for its LCA10 (Leber Congenital Amaurosis type 10 ) candidate EDIT-101 which will enable them for human testing of its CRISPR-based treatment for LCA10, a rare form of blindness. It will start enrolling approx 20 patients carrying IVS26 mutation in a phase 1/2 trial and is slated to become the first in vivo CRISPR genome editing treatment ever. 

As a consequence of the IND approval, Allergen will fund Editas with $25 million milestone payment. Under a $40 million agreement made earlier, Allergan agreed to develop and commercialize EDIT-101.

Editas registered in October for the IND. Earlier this month, Editas revealed the NIH decided that a Recombinant DNA Advisory Committee review of the protocol for the Stage I/II trial of EDIT-101 wasn’t necessary.

“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” Katrine Bosley, Editas’ president, and CEO, said in a statement.

Editas was earlier expected to submit EDIT-101 for approval by end of 2017, but owing to some manufacturing difficulties the process got delayed. Meanwhile, companies like CRISPR Therapeutics and partner Vertex took the opportunity to march ahead in the race. An ex-vivo CRISPR-based treatment for beta-thalassemia was initiated earlier this year but upon FDA’s orders, clinical trails were kept on hold which was lifted off ahead in the month of October.

See Also
LEAF 2019 - Life Science Education Ambition Fair Concluded Successfully

LCA10, the most common cause of inherited childhood blindness is caused by a mutation in the CEP290 gene. By the use of  EDIT-101, Editas is aiming to eliminate the mutation using CRISPR. In the process, it will remove the mutated nucleotide and surrounding DNA which will enable restoration of the normal protein expression and function of the remaining photoreceptor cells, arresting the further loss of vision for patients with LCA10.

As per a R&D deal signed in between Editas and Allergan last year in March, Editas received an upfront $90 million from Allergen in return of which Allergan gained exclusive access and licensing option to up to five of Editas’s early-stage CRISPR genome-editing programs targeting eye diseases, including EDIT-101.

Editas, the first CRISPR based gene editing research company was founded in November 2013 and bagged initial funding from $43 million from Third Rock Ventures, Polaris Ventures, and Flagship Ventures. Later Editas was able to pool in up to $120 Million in funding from Bill Gates along with 13 Other Investors including Google Ventures. www.editasmedicine.com.

Recently an announcement by a Chinese scientist who claims to create worlds first CRISPR edited babies has taken the scientific community by shock. But no proper documented evidence and research results have been provided yet which makes the claims by the Chinese scientist He Jiankui hard to believe. Investigations are still under process to validate its authenticity.

See Also
LEAF 2019 - Life Science Education Ambition Fair Concluded Successfully
--Learning is Earning--

Learn New Techniques

Perfection is her hobby, Reliability is a synonym, Editing is her passion, Excellence is her Goal, Tactfulness is in her genes, Yellow is her Fav color. Preety Suman is the name of the Professional on whom entire BioTecNika relies when it comes to its website.A Gold Medalist in Biotech from SRM University, Chennai with a 9.9 CGPA ( was awarded the Gold Medal by Honorable Prime Minister of India Shri Narendra Modi , as seen in the pic ), She decided to join forces with BioTecNika to ensure India's largest BioSciences Portal expands its reach to every city in India.She has redesigned the new avatar of BioTecNika from scratch and heads the most dynamic, vibrant and well informed Online Team at Biotecnika Info Labs Pvt Ltd